
|Articles|March 1, 2002
Greater IOP-lowering effect of drug seen in black population
Memphis, TN-Travoprost 0.004% ophthalmic solution (Travatan, Alcon) is an effective IOP-lowering medication in patients of all racial origins. However, travoprost reduces IOP more in black patients compared with non-black patients, and its efficacy in blacks exceeds that associated with both timolol (Timoptic, Merck) and latanoprost (Xalatan, Pharmacia), said Peter A. Netland, MD, PhD.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA grants Breakthrough Therapy Designation to Oculis’ privosegtor for optic neuritis
2
iOpeners with Nicole Bajic, MD: Mary Qiu, MD, on tailored NVG pathways
3
Long-lived Greenland sharks may point to new approaches for retinal disease
4
Orbital and retinal microvascular changes in thyroid eye disease
5












































